Actin cytoskeleton modulates ADMA-induced NF-kappaB nuclear translocation and ICAM-1 expression in endothelial cells

Medical Science Monitor

Volumn 17, Issue 9, 2011, Pages

  Wei Kang, Guo ^a   Dong Liang, Zhang ^a   Xin Xin, Wang ^a   Wei, Kong ^a   Qi Dong, Zhang ^a   Yu, Zhang ^a   Wen Hu, Liu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Actin cytoskeleton; ADMA; Endothelial cell; ICAM 1; NF kB

Indexed keywords

ACTIN; CYTOCHALASIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; JASPAMIDE; N(G),N(G) DIMETHYLARGININE;

ACTIN FILAMENT; ARTICLE; CELL CULTURE; DNA BINDING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STRESS FIBER; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 80054040458     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881927     Document Type: Article

References (41)

1. Vallance P, Leone A, Calver A et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992; 339(8793): 572-75
2. Kielstein JT, Boger RH, Bode-Boger SM et al: Asymmetric dimethylargi-nine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol, 1999; 10(3): 594-600
3. Caglar K, Yilmaz MI, Sonmez A et al: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int, 2006; 70: 781-87
4. Kielstein JT, Martens-Lobenhoffer J, Vollmer S et al: L-Arginine, ADMA, SDMA, creatinine, MDRD formula: detour to renal function testing. J Nephrol, 2008; 21: 959-61
5. Panichi V, Mantuano E, Paoletti S et al: Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol, 2008; 21: 38-44
6. Zoccali C, Benedetto FA, Maas R et al: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol, 2002; 13: 490-96
7. Fliser D, Kronenberg F, Kielstein JT et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol, 2005; 16: 2456-61
8. Ravani P, Tripepi G, Malberti F et al: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol, 2005; 16: 2449-55
9. Boger RH, Maas R, Schulze F et al: Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res, 2009; 60(6): 481-87
10. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens, 2008; 17(6): 609-15
11. Boger RH, Zoccali C: ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl, 2003; 4(4): 23-28
12. Jiang JL, Wang S, Li NS et al: The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells. Biochem Cell Biol, 2007; 85(1): 66-77
13. Xin HY, Jiang DJ, Jia SJ et al: Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells. Thromb Haemost, 2007; 97(5): 830-38
14. Smith CW, Rothlein R, Hughes BJ et al: Recognition of an endothelial determinant for CD 18-dependent human neutrophil adherence and transendothelial migration. J Clin Invest, 1988; 82(5): 1746-56
15. Smith CW, Marlin SD, Rothlein R et al: Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest, 1989; 83(6): 2008-17
16. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 1994; 76(2): 301-14
17. Doerschuk CM, Tasaka S, Wang Q: CD11/CD18-dependent and -independent neutrophil emigration in the lungs: how do neutrophils know which route to take. Am J Respir Cell Mol Biol, 2000; 23(2): 133-36
18. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 1996; 14: 649-83
19. Whiteside ST, Israel A: I kappa B proteins: structure, function and regulation. Semin Cancer Biol, 1997; 8(2): 75-82
20. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell, 2002; 109(Suppl.): S81-96
21. Yamamoto Y, Gaynor RB: IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci, 2004; 29(2): 72-79
22. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Annu Rev Immunol, 2000; 18: 621-63
23. Ben-Neriah Y: Regulatory functions of ubiquitination in the immune system. Nat Immunol, 2002; 3(1): 20-26
24. Rahman, A, Bando, M, Kefer J et al: Protein Kinase C-Activated Oxidant Generation in Endothelial Cells Signals Intercellular Adhesion Molecule-1 Gene Transcription. Mol Pharmacol, 1999; 55: 575-83
25. Ledebur HC, Parks TP: Transcriptional Regulation of the Intercellular Adhesion Molecule-1 Gene by Inflammatory Cytokines in Human Endothelial Cells. J Biol Chem, 1995; 270: 933-43
26. Minami T, Aird WC: Endothelial cell gene regulation. Trends Cardiovasc Med, 2005; 15: 174-84
27. Collins T, Read MA, Neish AS et al: Transcriptional regulation of en-dothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J, 1995; 9(10): 899-909
28. Fazal F, Minhajuddin M, Bijli KM et al: Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translo-cation in endothelial cells. J Biol Chem, 2007; 282(6): 3940-50
29. Wagner DD, Olmsted JB, Marder VJ: Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol, 1982; 95(1): 355-60
30. Kustermans G, Piette J, Legrand-Poels S: Actin-targeting natural compounds as tools to study the role of actin cytoskeleton in signal trans-duction. Biochem Pharmacol, 2008; 76(11): 1310-22
31. Bubb MR, Senderowicz AM, Sausville EA et al: Jasplakinolide, a cytotox-ic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem, 1994; 269(21): 14869-71
32. Price DT, Loscalzo J: Cellular adhesion molecules and atherogenesis. Am J Med, 1999; 107(1): 85-97
33. Eswarappa SM, Pareek V, Chakravortty D: Role of actin cytoskeleton in LPS-induced NF-kappaB activation and nitric oxide production in mu-rine macrophages. Innate Immun, 2008; 14(5): 309-18
34. Kustermans G, El Mjiyad N, Horion J et al: Actin cytoskeleton differentially modulates NF-kappaB-mediated IL-8 expression in myelomono-cytic cells. Biochem Pharmacol, 2008; 76(10): 1214-28
35. Babakov VN, Petukhova OA, Turoverova LV et al: RelA/NF-kappaB transcription factor associates with alpha-actinin-4. Exp Cell Res, 2008; 314(5): 1030-38
36. Nemeth ZH, Deitch EA, Davidson MT et al: Disruption of the actin cy-toskeleton results in nuclear factor-kappaB activation and inflammato-ry mediator production in cultured human intestinal epithelial cells. J Cell Physiol, 2004; 200(1): 71-81
37. Kustermans G, El Benna J, Piette J et al: Perturbation of actin dynamics induces NF-kappaB activation in myelomonocytic cells through an NADPH oxidase-dependent pathway. Biochem J, 2005; 387(Pt 2): 531-40
38. Irigoyen JP, Besser D, Nagamine Y: Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracel-lular signal-regulated kinase (ERK) signaling pathway. J Biol Chem, 1997; 272(3): 1904-9
39. Kim SJ, Hwang SG, Kim IC et al: Actin cytoskeletal architecture regulates nitric oxide-induced apoptosis, dedifferentiation, and cyclooxy-genase-2 expression in articular chondrocytes via mitogen-activated protein kinase and protein kinase C pathways. J Biol Chem, 2003; 278(43): 42448-56
40. Sotiropoulos A, Gineitis D, Copeland J et al: Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell, 1999; 98(2): 159-69
41. Posern G, Miralles F, Guettler S et al: Mutant actins that stabilise F-actin use distinct mechanisms to activate the SRF coactivator MAL. EMBO J, 2004; 23(20): 3973-83